Improvement of glucose tolerance by minimal doses of glipizide in obese subjects with different degrees of glucose intolerance

A. E. Pontiroli, M. G. Perfetti, G. Pozza

Research output: Contribution to journalArticle

Abstract

Obesity and impaired glucose tolerance (IGT) are risk factors for non insulin dependent diabetes mellitus (NIDDM) and for ischemic heart disease. Long term treatment of IGT subjects with diet and tolbutamide prevents progression of IGT to NIDDM. We have evaluated the lowest dose of glipizide, a second-generation sulfonylurea, able to improve glucose tolerance in response to oral glucose in 31 obese subjects, 12 with NIDDM, 9 with IGT and 10 with normal glucose tolerance (NGT). All subjects underwent four OGTTs, preceded by placebo and by different doses of glipizide (0.5, 1.0, 2.5 mg). Glucose tolerance was progressively improved by increasing glipizide doses in all groups, probably by peripheral mechanism and by enhanced insulin release.

Original languageEnglish
Pages (from-to)32-34
Number of pages3
JournalHormone and Metabolic Research, Supplement
Issue number26
Publication statusPublished - 1992

Fingerprint

Glipizide
Glucose Intolerance
Type 2 Diabetes Mellitus
Glucose
Medical problems
Insulin
Tolbutamide
Glucose Tolerance Test
Myocardial Ischemia
Obesity
Placebos
Diet
Nutrition

Keywords

  • C-peptide
  • diabetes
  • glipizide
  • impaired glucose tolerance
  • insulin
  • obesity
  • sulfonylureas

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

@article{48741c52eef047ada8c1f0561719e352,
title = "Improvement of glucose tolerance by minimal doses of glipizide in obese subjects with different degrees of glucose intolerance",
abstract = "Obesity and impaired glucose tolerance (IGT) are risk factors for non insulin dependent diabetes mellitus (NIDDM) and for ischemic heart disease. Long term treatment of IGT subjects with diet and tolbutamide prevents progression of IGT to NIDDM. We have evaluated the lowest dose of glipizide, a second-generation sulfonylurea, able to improve glucose tolerance in response to oral glucose in 31 obese subjects, 12 with NIDDM, 9 with IGT and 10 with normal glucose tolerance (NGT). All subjects underwent four OGTTs, preceded by placebo and by different doses of glipizide (0.5, 1.0, 2.5 mg). Glucose tolerance was progressively improved by increasing glipizide doses in all groups, probably by peripheral mechanism and by enhanced insulin release.",
keywords = "C-peptide, diabetes, glipizide, impaired glucose tolerance, insulin, obesity, sulfonylureas",
author = "Pontiroli, {A. E.} and Perfetti, {M. G.} and G. Pozza",
year = "1992",
language = "English",
pages = "32--34",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "26",

}

TY - JOUR

T1 - Improvement of glucose tolerance by minimal doses of glipizide in obese subjects with different degrees of glucose intolerance

AU - Pontiroli, A. E.

AU - Perfetti, M. G.

AU - Pozza, G.

PY - 1992

Y1 - 1992

N2 - Obesity and impaired glucose tolerance (IGT) are risk factors for non insulin dependent diabetes mellitus (NIDDM) and for ischemic heart disease. Long term treatment of IGT subjects with diet and tolbutamide prevents progression of IGT to NIDDM. We have evaluated the lowest dose of glipizide, a second-generation sulfonylurea, able to improve glucose tolerance in response to oral glucose in 31 obese subjects, 12 with NIDDM, 9 with IGT and 10 with normal glucose tolerance (NGT). All subjects underwent four OGTTs, preceded by placebo and by different doses of glipizide (0.5, 1.0, 2.5 mg). Glucose tolerance was progressively improved by increasing glipizide doses in all groups, probably by peripheral mechanism and by enhanced insulin release.

AB - Obesity and impaired glucose tolerance (IGT) are risk factors for non insulin dependent diabetes mellitus (NIDDM) and for ischemic heart disease. Long term treatment of IGT subjects with diet and tolbutamide prevents progression of IGT to NIDDM. We have evaluated the lowest dose of glipizide, a second-generation sulfonylurea, able to improve glucose tolerance in response to oral glucose in 31 obese subjects, 12 with NIDDM, 9 with IGT and 10 with normal glucose tolerance (NGT). All subjects underwent four OGTTs, preceded by placebo and by different doses of glipizide (0.5, 1.0, 2.5 mg). Glucose tolerance was progressively improved by increasing glipizide doses in all groups, probably by peripheral mechanism and by enhanced insulin release.

KW - C-peptide

KW - diabetes

KW - glipizide

KW - impaired glucose tolerance

KW - insulin

KW - obesity

KW - sulfonylureas

UR - http://www.scopus.com/inward/record.url?scp=0027008275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027008275&partnerID=8YFLogxK

M3 - Article

C2 - 1490690

AN - SCOPUS:0027008275

SP - 32

EP - 34

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 26

ER -